A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer (IPATunity150)

Status:

Opening Soon

II/III

Phase

2nd

Line of Therapy

Advanced / Metastatic

Disease Stage

Biomarker(s)

ER+, HER2-

Investigational

Product

Ipatasertib

AKT inhibitor (p.o.)

Treatment Arms

o Experimental: Phase 1b and Phase 3: Ipatasertib + Palbociclib +Fulvestrant

o Placebo Comparator: Phase 3: Placebo + Palbociclib + Fulvestrant